Compare MCR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCR | PALI |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 246.2M | 240.2M |
| IPO Year | N/A | 2019 |
| Metric | MCR | PALI |
|---|---|---|
| Price | $6.06 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 87.7K | ★ 3.1M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.52% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $5.57 | $0.55 |
| 52 Week High | $6.57 | $2.64 |
| Indicator | MCR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 46.09 | 41.38 |
| Support Level | $6.00 | $1.58 |
| Resistance Level | $6.38 | $2.02 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 59.68 | 33.09 |
MFS Charter Income Trust is a United States-based closed-end fund. Its investment objective is to seek high current income, but may also consider capital appreciation. The fund invests the assets in Debt Instruments, Corporate Bonds, U.S. Government Securities, Foreign Government Securities, Securitized Instruments, Derivatives, Principal Risks, Debt Management Risk, Investment Selection Risk, Interest Rate Risk, Credit Risk, Foreign Risks, Emerging Markets Risk, Currency Risk, Leveraging Risk, Operational and Cybersecurity Risk, Active and Frequent Trading, and etc of different market countries.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.